Positive results from recent pre-clinical studies support the potential of long-acting PASylated® nomacopan to advance toward IND/IMPD for clinical trials in …
Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
Four patients have been enrolled in the Phase 3 Part A clinical trial of nomacopan in severe pediatric hematopoietic stem cell transplant related (HSCT) …
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
NEW YORK and LONDON, July 7, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for …
Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies
NEW YORK and LONDON, June 13, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced …
Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2022
NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2022 PROXY FORM (CLICK TO VIEW AND DOWNLOAD) ANNUAL REPORT AND CONSOLIDATED FINANCIAL …
